DelveInsight has launched a new report on Pneumonia Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Pneumonia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Pneumonia, historical and forecasted epidemiology as well as the Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Pneumonia market report provides current treatment practices, emerging drugs, Pneumonia market share of the individual therapies, current and forecasted Pneumonia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pneumonia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
According to the National Foundation for Infectious Diseases, Pneumococcal disease (PD) is an infection caused by bacteria called Streptococcus pneumoniae or pneumococcus.Streptococcus pneumoniae is transmitted mainly through respiratory droplets and colonizes the nasopharynx. Infection of other parts of the body, resulting in disease, occur through direct spread or invasion of the bloodstream.Pneumococcal infections may be local or invasive. There are about 90 types of Streptococcus pneumoniae that cause a range of symptoms from relatively minor to very serious. Some types are more likely to cause infections in particular parts of the body than others, such as the sinuses and ear.
Request for :- free sample page
Epidemiology
The Pneumonia epidemiology division provide insights about historical and current Pneumonia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Report Key facts:-
1. As per the study by Zhang et al. titled “Clinical and economic burden of pneumococcal disease in US adults aged 19–64 years with chronic or immunocompromising diseases: an observational database study,” the incidence of invasive pneumococcal disease (IPD) was 3.62/100,000 person-years. Rate of IPD for adults with one at-risk condition was 3.7 times higher than healthy adults but 10.6 times higher for adults with ≥2 at-risk conditions.
2. The study conducted by Zhang et al. shows that adults with chronic lung disease were at the greatest risk of IPD as compared to healthy adults. The risk of IPD in adults with chronic liver disease was 7.2 times the risk in healthy adults, followed by chronic heart disease, diabetes mellitus, and asthma. The risk of IPD in adults with HIV was 17.4 times the risk in healthy adults, followed by asplenia, cancer, and organ transplant.
“According to Zhang et al., the rate per 100,000 person-years was 1.77 for people of ages 19–49 years and 6.63 for people of ages 50–64 years”
Key companies are working on Pneumonia disease that are given below:-
1. Merck Pharma Co.
2. Pfizer Pharma Co
3. Astellas Pharma Co
Name of drugs covered are given below:-
1. V114
2. 20vPNC
3. ASP3772
Table of contents
1. Key Insights
2. Executive Summary of Pneumonia
3. Competitive Intelligence Analysis for Pneumonia
4. Pneumonia: Market Overview at a Glance
4.1. Pneumonia Total Market Share (%) Distribution in 2017
4.2. Pneumonia Total Market Share (%) Distribution in 2030
5. Pneumonia: Disease Background and Overview
6. Patient Journey
7. Pneumonia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Pneumonia Treatment and Management
8.2. Pneumonia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Pneumonia Treatment
11. Marketed Products
12. Emerging Therapies
13. Pneumonia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Pneumonia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports:-
1. Pneumonia – Epidemiology Forecast to 2030
2. Bacterial Pneumonia – Pipeline Insights, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/